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ABSTRACT
Objective: Clozapine is known to cause cardiac side-effects, including myocarditis, pericarditis and cardiomyopathy. A 
50-year-old Malay man with schizoaffective disorder and tardive dyskinesia who developed transient tachycardia, low blood 
pressure and fever after 17 days of starting clozapine was studied.
Result: Elevated creatinine kinase at 532 U/l along with WBC and neutrophil count at 21.40 and 16.83 x 1071 respectively 
indicated an acute myocarditis. Additionally, pericardium involvement was suggested by V1-V4 ST elevation and absence of T 
wave inversion.
Conclusion: The emergence of tachycardia, low blood pressure and fever in patient who is recently started on clozapine 
treatment should be investigated for cardiac complications. Old age and concomitant treatment with sodium valproate possibly 
increased the risk of clozapine-induced cardiac side-effects.
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INTRODUCTION
Cardiovascular side effects of clozapine, including tachycardia and 
orthostatic hypotension, are relatively common but little attention is 
paid to them compared to agranulocytosis. The increasing number of 
clozapine related cardiac complications reported in the literature'-2’ have 
given rise to concern about the risk of acute cardiac side effects, includ­
ing myocarditis, pericarditis and cardiomyopathy, in patients treated 
with the drug. We document here case of clozapine-induced myocarditis 
and pericarditis with serial elevation of cardiac enzymes and ECG 
changes.
CASE REPORT
A 50-year-old Malay man with schizoaffective disorder and comor- 
bid amphetamine abuse was admitted for management of acute psycho­
sis. He was a smoker for the past 30 years. There was no history of dia­
betes mellitus, hypertension or other cardiovascular disease. His BMI 
was 19.9. Baseline ECG, renal and liver function were normal. 
Emerging tardive dyskinesia (TD) over a year period necessitated the 
use of clozapine, commenced at 25 mg daily orally and increased to 100 
mg daily over 2 weeks. Other antipsychotics were stopped including 
olanzapine and monthly fluphenazine decanoate depot which otherwise 
he had received just prior to the admission. Sodium valproate 500 mg 
BD was continued. This treatment resulted in improvement of psychotic 
symptoms as well as the tardive dyskinesia.
Seventeen days later whilst on clozapine 100 mg daily, the patient 
developed transient tachycardia (100 bpm lasting for 12 hours), low 
blood pressure and fever (3913). Nevertheless, he denied any chest pain 
or dyspnea. ECG showed ST elevation at V1-V4 and absence of T wave 
inversion indicating acute pericarditis. Blood tests now revealed ESR 36 
mm/hr, CRP 106 mg/1 signifying an acute inflammatory process. Raised
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creatinine kinase at 532 U/l indicated presence of acute myocarditis. 
WBC and neutrophil count was grossly elevated at 21.40 and 16.83 x 
1071 respectively. Other haematological and electrolyte indices were 
within normal range. Clozapine was immediately stopped and intrave­
nous hydrocortisone 100 mg was given for 3 days. His vital signs were 
closely monitored. Repeat CK and CKMB after 2 days were 240 and 11 
U/l respectively. Repeat ECG was normalized to the baseline. 
Transthoracic echocardiography performed 4 days later revealed normal 
ventricular size and function with no pericardial effusion. The patient 
was discharged well 1 week later.
DISCUSSION
Hypersensitivity myocarditis is particularly difficult to recognise 
because the clinical features characteristic of a drug hypersensitivity 
reaction including non-specific skin rash, malaise, fever, and eosinophil- 
ia are absent in most cases. Drugs associated with hypersensitivity myo­
carditis include clozapine, sulfonamide antibiotics, methyldopa, and 
some anti-seizure drugs3’.
Our diagnosis of clozapine-induced myocarditis and pericarditis 
was one of exclusion, supported by its temporal relationship of onset 
with clozapine initiation and remission upon drug cessation. Whilst 
tachycardia is common side effect of clozapine2’, high grade fever and 
low blood pressure hinted more serious cardiovascular side effects. The 
diagnosis of myocarditis was very likely considering onset of these new 
symptoms were within 45 days of commencing clozapine with raised 
CK and CKMB above 2 upper limit of normal4’. Other possible causes, 
particularly acute myocardial infarction and neuroleptic malignant syn­
drome, were ruled out.
ECG abnormalities in patients treated with clozapine were common, 
mostly being nonspecific benign abnormality in T wave occurring up to 
one third of patients during the initial stage of the treatment5’. In this 
case, widespread ST elevation with non-inverted T wave was highly
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indicative of acute pericarditis. There was no indication of other serous 
membrane inflammation, such the pleura, or effusion.
The most striking feature about myocarditis is the wide diversity of 
nonspecific symptoms that occur in afflicted patients and the fact that it 
may occur even at usual therapeutic doses. Therefore, it is important to 
identify those patients at risk. A recent study of 105 cases, with time to 
onset of 10-33 days, and 296 controls found concomitant sodium val­
proate more than doubled the risk (odd ratio 2.59) and each successive 
decade in age associated with a 31% increase in risk of myocarditis61.
Non-fatal outcome of this case was largely attributed to early diag­
nosis and treatment of the condition. Factors that had been associated 
with fatal clozapine-induced myocarditis include obesity (BMI > 30 kg/ 
m2), longer duration of clozapine treatment (> 17 days) and CK > 1,000 
U/l were absent in this case71.
Poor quality o f life is independently associated with TD!) and 
depressive symptoms” in schizophrenia patients. Management of TD, 
therefore, is an important aspect of overall patient management. The 
patient was not re-challenged with clozapine mainly because the indica­
tion for clozapine in this case was emerging tardive dyskinesia rather 
than lack of response to antipsychotics. Although, tardive dyskinesia is 
associated with cumulative exposure to antipsychotics, the risk can be 
reduced by minimizing the use of typical antipsychotics. Whether 
patients could be rechallenged after myocarditis remains unclear as 
there were only few reported cases in the literature101.
CONCLUSION
The development of tachycardia, low blood pressure and fever in 
patient who is recently started on clozapine treatment should be investi­
gated for cardiac complications such as myocarditis or pericarditis. 
Older age and concomitant treatment with sodium valproate may 
increase the risk.
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